New hope for rare ovarian cancer: drug shows promise after immunotherapy fails
NCT ID NCT07168083
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This study tests a drug called sacituzumab in 22 people with a rare and aggressive type of ovarian cancer (clear cell carcinoma) whose tumors grew despite immunotherapy. The drug is an antibody-drug conjugate that targets a protein on cancer cells to deliver chemotherapy directly. Researchers want to see if it can shrink tumors and improve survival, with manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab (SKB264), an antibody-drug conjugate targeting Trop-2
What this could lead to
If it works, this could offer a new treatment option for patients with ovarian clear cell carcinoma who have run out of effective therapies after immunotherapy.
What could go wrong
This is a small, early-stage study with only 22 participants, so results may not apply to everyone. The drug may cause side effects, and it is not yet proven to be better than existing options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.